Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

被引：10
|
作者：
Schipilliti, Francesca Matilde [1 ]
Drittone, Denise [1 ]
Mazzuca, Federica [2 ]
La Forgia, Daniele [3 ]
Guven, Deniz Can [4 ]
Rizzo, Alessandro [3 ]
机构：
[1] Univ Sapienza Rome, St Andrea Hosp, Oncol Dept, Rome, Italy
[2] Sapienza Univ, Dept Clin & Mol Med, Oncol Unit, Azienda Osped Univ St Andrea, Rome, Italy
[3] IRCCS Ist Tumori Giovanni Paolo II, Bari, Italy
[4] Hacettepe Univ, Dept Med Oncol, Canc Inst, TR-06100 Ankara, Turkiye
来源：
HELIYON | 2024年 / 10卷 / 07期
关键词：
Breast cancer; Triple -negative breast cancer; ADC; Antibody -drug conjugates; Dato-DXd; Datopotamab deruxtecan; TRASTUZUMAB EMTANSINE; SACITUZUMAB GOVITECAN; PHASE I/II; OPEN-LABEL; SURVIVAL; EFFICACY; TROP-2;
D O I：
10.1016/j.heliyon.2024.e28385
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.
引用
收藏
页数：7
相关论文
共 50 条
  • [21] Emerging Novel Therapeutics in Triple-Negative Breast Cancer
    Lyons, Tomas G.
    Traina, Tiffany A.
    BREAST CANCER METASTASIS AND DRUG RESISTANCE: CHALLENGES AND PROGRESS, 2ND EDITION, 2019, 1152 : 377 - 399
  • [22] Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer
    Boscolo Bielo, Luca
    Trapani, Dario
    Curigliano, Giuseppe
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (07) : 789 - 801
  • [23] Association between stomatitis and treatment efficacy with novel TROP2-directed antibody drug conjugate (ADC), datopotamab deruxtecan, in patients with metastatic cancer
    Abelman, Rachel O.
    Spring, Laura M.
    Ryan, Phoebe K.
    Fell, Geoffrey
    Juric, Dejan
    Heist, Rebecca S.
    Bardia, Aditya
    CANCER RESEARCH, 2023, 83 (07)
  • [24] Novel Treatment Approaches for Triple-Negative Breast Cancer
    Telli, Melinda L.
    Ford, James M.
    CLINICAL BREAST CANCER, 2010, 10 : E16 - E22
  • [25] Triple-Negative Breast Cancer
    Winkeljohn, Debra L.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2008, 12 (06) : 861 - 863
  • [26] Triple-Negative Breast Cancer
    Hudis, Clifford A.
    CANCER JOURNAL, 2010, 16 (01): : 10 - 11
  • [27] Triple-Negative Breast Cancer
    Quyen D. Chu
    King, Tari
    Hurd, Thelma
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2012, 2012
  • [28] Triple-negative breast cancer
    Chacon, Reinaldo D.
    Costanzo, Maria V.
    BREAST CANCER RESEARCH, 2010, 12
  • [29] Triple-negative breast cancer
    Stockmans, Gert
    Deraedt, Karen
    Wildiers, Hans
    Moerman, Philippe
    Paridaens, Robert
    CURRENT OPINION IN ONCOLOGY, 2008, 20 (06) : 614 - 620
  • [30] Triple-Negative Breast Cancer
    Foulkes, William D.
    Smith, Ian E.
    Reis-Filho, Jorge S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20): : 1938 - 1948
12345